MarketVIEW: diabetes vaccines

News provided by

Jan 07, 2014, 10:22 ET

LONDON, Jan. 7, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Diabetes is a metabolic disorder where the pancreas produces little or no insulin (Type I) OR cells do not respond appropriately to insulin that is produced (Type II). It is estimated that the global prevalence of diabetes is estimated at over 371 million people, a number predicted to rise significantly by 2030. Diabetes, although manageable, can lead to a number of complications, many of which can be fatal. It is estimated that 4.6 million people aged between 20-79 died from diabetes in 2011.

Since Type 1 diabetes is an autoimmune disorder, there is a plausible role for a vaccine which may prevent or slow the damage being caused to the beta-cells in the pancreas. Consequently several different approaches have been explored involving immunomodulatory candidates. The most advanced clinical candidate has been Diamyd's, GAD (recombinant human glutamic acid decarboxylase protein) based therapy which is currently in Phase II clinical testing.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of diabetes vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with timeframe, pricing and penetration estimates for all adult/pediatric risk groups depending on stage of diabetes/risk profile. The product also includes an up-to-date review of disease epidemiology and competitor R&D pipeline activity.

THIS PRODUCT IS COMPOSED OF SUMMARY PRESENTATION + 1 MODEL (optional)
Author's note
Executive Summary
Commercial model: key outputs
Diabetes vaccine: available global market to 2030
Diabetes vaccine: predicted global demand
Diabetes vaccine: available market per country (USD $) to 2030
Diabetes vaccine: available US market to 2030 (base case)
Diabetes vaccine: available EU market to 2030 (base case)
Diabetes: disease background and epidemiology
Diabetes: brief disease background
Diabetes: clinical types
Diabetes: global epidemiology
Diabetes: US statistics
Diabetes: UK statistics
Diabetes: symptoms
Diabetes: prediabetes
Diabetes: diagnosis
Diabetes: treatment overview
Diabetes: treatment guidelines
Diabetes: impact of the disease
Diabetes: impact of the disease – complications
Diabetes: impact of the disease – complications
Diabetes: economic impact of the disease
Diabetes: impact of the disease in the UK
Diabetes vaccines: summary of development to date
The role of a diabetes vaccine
Diabetes vaccine approaches
Diabetes vaccines in development
The Diamyd approach
Diabetes vaccine: modelling commercial potential
Diabetes vaccine: target product profile
Addressable vaccine populations
Diabetes vaccine: model strategy
Diabetes forecast: population flow
Commercial model assumptions: overall
Commercial model assumptions by country
Vaccine coverage assumptions by country (all cases)
Bibliography
Disclaimer
About VacZine Analytics

PAGES: ~55 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand models (MS Excel-based)

Title sheet
TOTAL CHARTS
CHARTS – VALUE (high)
CHARTS – VALUE (base)
CHARTS – VALUE (low)
CHARTS – VOLUME (high)
CHARTS – VOLUME (base)
CHARTS – VOLUME (low)
Value summary (Total market)
Volume summary (Total market)
US (high)
Canada (high)
UK (high)
Germany (high)
France (high)
Spain (high)
Italy (high)
Australia (high)
Japan (high)
US (base)
Canada (base)
UK (base)
Germany (base)
France (base)
Spain (base)
Italy (base)
Australia (base)
Japan (base)
US (low)
Canada (low)
UK (low)
Germany (low)
France (low)
Spain (low)
Italy (low)
Australia (low)
Japan (low)
Assumptions